Antibody persistence after pneumococcal conjugate vaccination in patients with chronic lymphocytic leukemia
| Autor: | Helena Käyhty, Maija Itälä-Remes, Heini Huhtala, Vesa Lindström, Urpu Salmenniemi, Janne Aittoniemi, Marjatta Sinisalo |
|---|---|
| Přispěvatelé: | Yhteiskuntatieteiden tiedekunta - Faculty of Social Sciences, University of Tampere |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Serotype
Male Heptavalent Pneumococcal Conjugate Vaccine Time Factors Chronic lymphocytic leukemia Immunology Short Report Aftercare medicine.disease_cause complex mixtures Pneumococcal conjugate vaccine Pneumococcal Infections 03 medical and health sciences 0302 clinical medicine immune system diseases Syöpätaudit - Cancers hemic and lymphatic diseases Streptococcus pneumoniae medicine Immunology and Allergy Humans neoplasms Aged Pharmacology Aged 80 and over biology business.industry Sisätaudit - Internal medicine Middle Aged ta3121 medicine.disease Antibodies Bacterial Leukemia Lymphocytic Chronic B-Cell 3. Good health Vaccination Pneumococcal infections 030220 oncology & carcinogenesis biology.protein Female Antibody business 030215 immunology medicine.drug |
| Zdroj: | Human Vaccines and Immunotherapeutics. 14(6):1-4 |
| ISSN: | 2164-5515 |
| DOI: | 10.1080/21645515.2018.1436424 |
| Popis: | Patients with chronic lymphocytic leukemia (CLL) are at a high risk for infections caused by Streptococcus pneumoniae. A pneumococcal conjugate vaccine (PCV) can induce a significant antibody response for some CLL patients. In this study we investigated antibody persistence after PCV7 in patients with CLL. The study material comprised 24 patients with CLL and 8 immunocompetent controls. The median antibody concentrations five years after PCV7 were lower for six pneumococcal serotypes in patients with CLL compared to controls, but the difference was not statistically significant. Depending on the serotype, the percentage of the CLL patients with antibody levels suggested to provide protection against invasive pneumococcal disease (IPD) varied from 29 to 71% five years after vaccination. This data suggests that PCV could result in antibody persistence at least five years in CLL patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|